PureTech Health

December 2023 said the Board may declare special dividends or buybacks; $100m tender offer set out in March 2024.

“The PureTech Board may declare special dividends and/or share buybacks as part of an overall returns strategy.”20 Dec 2023 · PRTC Year End Update & Outlook for 2024

Launched 20 May rather than early May; completed 24 June, repurchasing $100m of shares.

“The Tender Offer opens today 20 May 2024.”20 May 2024 · Tender Offer “In total 31,540,670 Ordinary Shares (including Ordinary Shares represented by ADSs) will be purchased in accordance with the terms and subject to the conditions of the Tender Offer at the Tender Price, for a total cost of $100 million.”24 Jun 2024 · Result of Tender Offer

FDA approved KarXT (Cobenfy) on 27 September 2024; PureTech received $29m milestones.

27 Sep 2024 · KarXT/Cobenfy Approved by FDA; PRTC Receives $29M

Topline results announced 16 December 2024, meeting primary and key secondary endpoints.

“The trial achieved its primary endpoint based on the prespecified Bayesian analysis, with a 98.5% posterior probability. This means there is a 98.5% probability that the pooled deupirfenidone arms were superior to placebo in slowing the rate of lung function decline in people with IPF, as measured by forced vital capacity (FVC) at 26 weeks. The trial also successfully demonstrated a dose-dependent response.”16 Dec 2024 · PRTC's Ph2b in IPF Successful; New SOC Potential

Not yet due.

Design update came 8 December 2025 (Q4), when FDA agreement on the Phase 3 design was announced.

“Phase 3 SURPASS-IPF trial remains on track to be initiated by PureTech's Founded Entity, Celea Therapeutics, in the first half of 2026”8 Dec 2025 · Successful FDA Meeting; IPF Phase 3 in 1H26

Timing moved to Q4 2025; efficacy data came 3 November and 5 December 2025.

“topline efficacy readout and overall survival data expected in Q4 2025 and 1H 2026, respectively”3 Nov 2025 · New LYT-200 AML Data + Update at ASH

Results reported 13 August 2025, but the trial missed its primary endpoint.

“today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC).”13 Aug 2025 · PRTC's Vedanta Announces VE202 Phase 2 Results “endoscopic and clinical responses were assessed using standardized criteria, and the observed response rates in the VE202 group were not statistically different from those in the placebo group.”13 Aug 2025 · PRTC's Vedanta Announces VE202 Phase 2 Results

April 2026 data reported response rates; Phase 2 plan followed in September 2026. Final survival data not confirmed.

“Initial median overall survival of 13.2 months observed in the combination cohort at the proposed Phase 2 dose, exceeding expected late-line relapsed/refractory setting survival of <2.5 months; overall survival data at this dose continue to mature with final results expected in 1H 2026”5 Dec 2025 · PRTC's Gallop: Positive Initial Topline AML Data “Due to the number of patients alive at the time of study completion (50%), the upper bound of overall survival could not be calculated; therefore, the median overall survival for this cohort of 8.2 months is not considered fully mature.”22 Apr 2026 · PRTC's Gallop: Positive Ph1 Topline MDS & AML Data

Targeted early Q3 2026 by April; $180m financing completed 2 July 2026, just after the H1 deadline.

“PureTech Health plc (LSE: PRTC) ("PureTech", "Company") today announces that its Founded Entity, Celea Therapeutics Inc. ("Celea"), has completed a $180 million financing and associated asset transfer from PureTech (the "Transaction") with participation from a syndicate comprising top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and founder PureTech, alongside a large, U.S.-based healthcare-focused fund and a leading sovereign wealth fund (the "Celea Investors"). The Transaction establishes Celea as an independently funded company, with proceeds supporting the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial of deupirfenidone (LYT-100).”2 Jul 2026 · $180M & Asset Transfer

Goal slipped from end-2025 to H1 2026; first patient dosed 13 July 2026 after financing closed 2 July.

“Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care”2 Jul 2026 · $180M & Asset Transfer

Not yet due.

First patient dosed in Phase 2a on 7 October 2026.

7 Oct 2026 · PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated

Not yet due.

Target moved from 2026 to Q1 2027, then H1 2027.

“Gallop intends to pursue third-party capital to support a potentially registration-enabling trial in R/R HR-MDS, with the round targeted to close in the first quarter of 2027.”29 Apr 2026 · Final Results “PureTech intends to leverage external capital to support the continued development of LYT-200 through the completion of the Phase 2 trial and expects to secure capital in the first half of 2027.”21 Sep 2026 · PRTC's Gallop: Positive FDA Meeting & Fast Track

Not yet due.